GILD
NASDAQHealthcareLoading…
Gilead Sciences, Inc. - Common Stock
Sector: Healthcare•United States•Market Cap: $171.6B
Related News
Latest stories connected to GILD
10/12More news →
- RS 76Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook?Zacks Investment Research•7h ago•Original source
- RS 76Gilead Strengthens Inflammation Portfolio With Ouro Medicines DealZacks Investment Research•3d ago•Original source
- RS 76Gilead Sciences to acquire Ouro Medicines, expanding autoimmune therapy portfolioProactive Investors•3d ago•Original source
- RS 76Gilead to Buy Ouro Medicines for $2.2 Billion. ‘Immune Reset' Is Key to Future Gains.Barrons•3d ago•Original source
- RS 76Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending StockZacks Investment Research•Mar 19, 2026•Original source
- RS 76Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to KnowZacks Investment Research•Mar 18, 2026•Original source
- RS 76Gilead Sciences, Inc. (GILD) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha•Mar 11, 2026•Original source
- RS 76Gilead Sciences (GILD) Outperforms Broader Market: What You Need to KnowZacks Investment Research•Mar 9, 2026•Original source
- RS 76Why Gilead Sciences (GILD) is a Top Value Stock for the Long-TermZacks Investment Research•Mar 6, 2026•Original source
Financials
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|
| Revenue | 29.44B | 28.75B | 27.12B | 27.28B | 27.30B | 24.69B | 22.45B | 22.13B | 26.11B | 30.39B |
| Cost of Revenue | 3.92B | 6.25B | 6.50B | 5.66B | 6.60B | 4.57B | 4.67B | 4.85B | 4.37B | 4.26B |
| Gross Profit | 25.52B | 22.50B | 20.62B | 21.62B | 20.70B | 20.12B | 17.77B | 17.27B | 21.74B | 26.13B |
| Research and Development Expenses | 5.69B | 5.91B | 5.72B | 4.98B | 4.60B | 5.04B | 4.05B | 3.92B | 3.73B | 5.10B |
| General and Administrative Expenses | 0 | 2.64B | 2.82B | 4.89B | 4.51B | 4.32B | 0 | 0 | 0 | 0 |
| Selling and Marketing Expenses | 0 | 3.45B | 3.27B | 778.00M | 735.00M | 795.00M | 0 | 0 | 0 | 0 |
| Selling General and Administrative Expenses | 5.71B | 6.09B | 6.09B | 5.67B | 5.25B | 5.11B | 4.38B | 4.06B | 3.88B | 3.40B |
| Other Expenses | 2.31B | 8.84B | 1.21B | 3.64B | 939.00M | 5.89B | 0 | 0 | 0 | 0 |
| Operating Expenses | 13.71B | 20.84B | 13.01B | 14.29B | 10.79B | 16.05B | 8.44B | 7.98B | 7.61B | 8.50B |
| Cost and Expenses | 17.63B | 27.09B | 19.51B | 19.95B | 17.39B | 20.62B | 13.11B | 12.83B | 11.98B | 12.76B |
| Net Interest Income | -1.02B | -696.00M | -568.00M | -829.00M | -1.00B | -984.00M | -995.00M | -1.08B | -1.12B | -964.00M |
| Interest Income | 0 | 281.00M | 376.00M | 106.00M | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.02B | 977.00M | 944.00M | 935.00M | 1.00B | 984.00M | 995.00M | 1.08B | 1.12B | 964.00M |
| Depreciation and Amortization | 2.76B | 2.77B | 2.69B | 2.10B | 2.05B | 1.48B | 1.40B | 1.43B | 1.29B | 1.16B |
| EBITDA | 10.82B | 4.43B | 10.50B | 8.85B | 11.33B | 4.13B | 7.56B | 10.30B | 15.93B | 19.22B |
| EBIT | 10.82B | 1.67B | 7.80B | 6.75B | 9.28B | 2.65B | 6.16B | 8.88B | 14.65B | 18.06B |
| Non Operating Income Excluding Interest | 997.00M | -5.00M | -198.00M | 581.00M | 639.00M | 1.42B | -1.87B | -676.00M | -523.00M | -428.00M |
| Operating Income | 11.82B | 1.66B | 7.61B | 7.33B | 9.92B | 4.07B | 4.29B | 8.20B | 14.12B | 17.63B |
| Total Other Income Expenses Net | -2.02B | -972.00M | -746.00M | -1.52B | -1.64B | -2.40B | 873.00M | -401.00M | -595.00M | -536.00M |
| Income Before Tax | 9.80B | 690.00M | 6.86B | 5.81B | 8.28B | 1.67B | 5.16B | 7.80B | 13.53B | 17.10B |
| Income Tax Expense | 1.29B | 211.00M | 1.25B | 1.25B | 2.08B | 1.58B | -204.00M | 2.34B | 8.88B | 3.61B |
| Net Income From Continuing Operations | 8.51B | 479.00M | 5.61B | 4.57B | 6.20B | 89.00M | 5.36B | 5.46B | 4.64B | 13.49B |
| Net Income From Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Adjustments To Net Income | 0 | 1.00M | 1.00M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | 8.51B | 480.00M | 5.67B | 4.59B | 6.20B | 123.00M | 5.36B | 5.46B | 4.64B | 13.49B |
| Net Income Deductions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrom Line Net Income | — | — | — | — | — | — | — | — | — | — |
| EPS | 6.84 | 0.38 | 4.54 | 3.66 | 4.96 | 0.1 | 4.24 | 4.2 | 3.54 | 10.08 |
| EPS Diluted | 6.78 | 0.38 | 4.5 | 3.64 | 4.93 | 0.1 | 4.22 | 4.17 | 3.51 | 9.94 |
| Weighted Average SHS Out | 1.24B | 1.25B | 1.25B | 1.25B | 1.26B | 1.26B | 1.27B | 1.30B | 1.31B | 1.34B |
| Weighted Average SHS Out Dil | 1.25B | 1.25B | 1.26B | 1.26B | 1.26B | 1.26B | 1.28B | 1.31B | 1.32B | 1.36B |
| Fiscal Year (FMP) | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K |
| Gross Profit Margin | 0.87 | 0.78 | 0.76 | 0.79 | 0.76 | 0.81 | 0.79 | 0.78 | 0.83 | 0.86 |
| R&D to Revenue | 0.19 | 0.21 | 0.21 | 0.18 | 0.17 | 0.2 | 0.18 | 0.18 | 0.14 | 0.17 |
| SG&A to Revenue | 0 | 0.09 | 0.1 | 0.18 | 0.17 | 0.17 | 0 | 0 | 0 | 0 |
| Interest Burden | 0.91 | 0.41 | 0.88 | 0.86 | 0.89 | 0.63 | 0.84 | 0.88 | 0.92 | 0.95 |
| EBIT Margin | 0.37 | 0.06 | 0.29 | 0.25 | 0.34 | 0.11 | 0.27 | 0.4 | 0.56 | 0.59 |
| EBITDA Margin | 0.37 | 0.15 | 0.39 | 0.32 | 0.41 | 0.17 | 0.34 | 0.47 | 0.61 | 0.63 |
| EBT per EBIT | 0.83 | 0.42 | 0.9 | 0.79 | 0.83 | 0.41 | 1.2 | 0.95 | 0.96 | 0.97 |
| Effective Tax Rate | 0.13 | 0.31 | 0.18 | 0.21 | 0.25 | 0.95 | -0.04 | 0.3 | 0.66 | 0.21 |
| Tax Burden | 0.87 | 0.7 | 0.83 | 0.79 | 0.75 | 0.07 | 1.04 | 0.7 | 0.34 | 0.79 |
| Cont. Operations Profit Margin | 0.29 | 0.02 | 0.21 | 0.17 | 0.23 | 0 | 0.24 | 0.25 | 0.18 | 0.44 |
| Bottom Line Profit Margin | 0.29 | 0.02 | 0.21 | 0.17 | 0.23 | 0 | 0.24 | 0.25 | 0.18 | 0.44 |
| Operating Cycle | 467.62 | 155.96 | 163.1 | 161.15 | 149.53 | 206.68 | 130.23 | 116.1 | 120.73 | 190.16 |
| Fwd PEG Ratio | 0.01 | -2.62 | 0.74 | -0.9 | 0 | -6.09 | 16.09 | 0.8 | -0.31 | -0.38 |
| Earnings Yield | 0.06 | 0 | 0.06 | 0.04 | 0.07 | 0 | 0.07 | 0.07 | 0.05 | 0.14 |
| Income Quality | 1.18 | 22.56 | 1.41 | 1.98 | 1.84 | 66.41 | 1.7 | 1.54 | 2.56 | 1.26 |